4 Top Nifty Pharma Stocks to Watch for Future Multibagger Potential: Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin
- October 23, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Sun Pharma Rs 1,758. Divi’s Labs Rs 9,162. Torrent Pharma Rs 4,615.30. Lupin Rs 1,922. Market caps from Rs 89,592 crore to Rs 4.22 lakh crore. Data as of 22 Oct 2026.
Quick Answer
Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin are the 4 picks in this Nifty Pharma stocks watchlist, with market caps between Rs 89,592 crore and Rs 4.22 lakh crore. Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22, while Divi’s Labs offers the strongest latest-quarter profit growth at 65.50%. PE ratios run from 16.14 to 82.05, so compare each one with its industry PE before investing. All figures are as of 22 October 2026.
Nifty Pharma stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin meet that test, with market caps from Rs 89,592 crore to Rs 4.22 lakh crore and Sun Pharma offering the fastest profit growth, 35.75% a year since FY22. Each of these companies has membership of the Nifty Pharma index, and net profit rose in FY26 and in the latest quarter.
This list covers companies with membership of the Nifty Pharma index, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. The companies here range from midcaps to largecaps in size. Investors screening Nifty Pharma stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 22 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Nifty Pharma Stocks and Why Do They Attract Multibagger Interest?
Nifty Pharma stocks are shares of the drug makers that form India’s pharmaceutical index. The four here cover a specialty and generics leader, an API and custom synthesis maker, a domestic formulations company and a global generics player.
Pharma earnings mix domestic demand with exports, which spreads the risk. For Nifty Pharma stocks, rising profit adds to the case. A sensible way to study Nifty Pharma stocks is to look at profit growth, returns and valuation side by side. Below, each of Nifty Pharma stocks gets its own breakdown of growth, returns and valuation. Treat Nifty Pharma stocks as a research list, since share prices and rankings change with every earnings season.
Nifty Pharma Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 22 October 2026. Lupin has the lowest PE of the group at 16.14, while Torrent Pharma posts the highest return on equity at 25.49%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,758 | 4,22,427 | 34.86 | 36.42 | 13.74% | 0.06 | 1,583.70 to 2,046.90 |
| Divi’s Laboratories | 9,162 | 2,39,982 | 82.05 | 36.42 | 15.32% | 0.00 | 5,647.50 to 9,740.00 |
| Torrent Pharmaceuticals | 4,615.30 | 1,75,196 | 81.26 | 36.42 | 25.49% | 1.79 | 3,480.60 to 5,250.00 |
| Lupin | 1,922 | 89,592 | 16.14 | 36.42 | 23.76% | 0.29 | 1,900.00 to 2,529.50 |
Sun Pharma: 35.75% Profit CAGR Since FY22
Sun Pharmaceutical Industries is one of India’s largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.
In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 110.81% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026. The stock trades at a PE of 34.86 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%.
Divi’s Labs: Debt-to-Equity of 0.00
Divi’s Laboratories makes active pharmaceutical ingredients and intermediates and runs a large custom synthesis business for global drug companies. It reported FY26 revenue of Rs 11,067 crore, up 13.95% year on year, and net profit of Rs 2,568 crore, up 17.21%. Revenue has compounded at 5.09% a year since FY22. Operating margin was 36.70% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.
The stock trades at a PE of 82.05 against an industry PE of 36.42, with a return on equity of 15.32%. In the June 2026 quarter, revenue rose 24.32% to Rs 3,144 crore and net profit grew 65.50% to Rs 902 crore. The share price has gained 71.04% over five years and 38.43% over the past year. Foreign investors raised their holding from 19.39% in September 2025 to 20.38% in September 2026.
Torrent Pharma: 28.79% Profit CAGR Since FY22
Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.
In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 81.26 against an industry PE of 36.42, with a return on equity of 25.49%.
Lupin: Revenue Up 26.76% in FY26
Lupin is a global pharmaceutical company with a large presence in the United States, India and other markets across generics, branded drugs and respiratory products. It reported FY26 revenue of Rs 29,038.95 crore, up 26.76% year on year, and net profit of Rs 5,355.47 crore, up 61.98%. Revenue has compounded at 14.98% a year since FY22. Operating margin was 31.06% in FY26. The debt-to-equity ratio is 0.29.
The stock trades at a PE of 16.14 against an industry PE of 36.42, below the sector average, with a return on equity of 23.76%. In the June 2026 quarter, revenue rose 32.45% to Rs 8,407.21 crore and net profit grew 16.01% to Rs 1,416.98 crore. The share price has gained 111.00% over five years. Foreign investors raised their holding from 21.25% in June 2025 to 22.42% in June 2026.
Nifty Pharma Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these Nifty Pharma stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Sun Pharma | 61,673.94 | 11,564.52 | 12.69% | 11.62% | 11.93% | 32.52% |
| Divi’s Labs | 11,067 | 2,568 | 13.95% | 5.09% | 24.32% | 42.82% |
| Torrent Pharma | 13,886.15 | 2,138.18 | 20.34% | 12.38% | 56.29% | 33.73% |
| Lupin | 29,038.95 | 5,355.47 | 26.76% | 14.98% | 32.45% | 31.40% |
Check the Univest Screener for live data on these Nifty Pharma stocks
Institutional Holding in Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin
Institutional holding shows who is backing these Nifty Pharma stocks alongside the promoter. The table uses the latest reported quarter for each. Lupin has the deepest institutional backing, with FII and DII together holding 47.07% as of June 2026. Domestic institutions increased their holding over the past year in Sun Pharma (from 20.23% to 22.27%) and Torrent Pharma (from 9.28% to 12.87%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Sun Pharma | 52.68% | 14.36% | 22.27% | 10.70% | September 2026 |
| Divi’s Labs | 51.88% | 20.38% | 19.17% | 8.58% | September 2026 |
| Torrent Pharma | 60.78% | 17.97% | 12.87% | 8.38% | July 2026 |
| Lupin | 46.85% | 22.42% | 24.65% | 6.08% | June 2026 |
Risks to Weigh in Nifty Pharma Stocks
Being careful with Nifty Pharma stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Divi’s Labs trades at a PE of 82.05 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Nifty Pharma Stocks
Picking from Nifty Pharma stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (36.42) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin live prices.
Conclusion
Among Nifty Pharma stocks, Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22, Divi’s Labs for the strongest latest-quarter profit growth at 65.50%, Torrent Pharma for the highest return on equity at 25.49% and Lupin for the lowest PE of the group at 16.14. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing Nifty Pharma stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Nifty Pharma Stocks to Watch
Which are the best Nifty Pharma stocks to watch for multibagger potential?
Ans. Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin are the 4 names this list highlights, with market caps of Rs 4,22,427 crore, Rs 2,39,982 crore, Rs 1,75,196 crore and Rs 89,592 crore respectively. Sun Pharma is notable for the fastest profit growth, 35.75% a year since FY22. Divi’s Labs stands out for the strongest latest-quarter profit growth at 65.50%. Torrent Pharma offers the highest return on equity at 25.49%. Lupin brings the lowest PE of the group at 16.14. These are watchlist names for Nifty Pharma stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Torrent Pharma a good stock for long-term investors?
Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 81.26 against an industry PE of 36.42 and a market cap of Rs 1,75,196 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in Nifty Pharma stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Sun Pharma become a multibagger from here?
Ans. Sun Pharma has already gained 110.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Nifty Pharma stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 34.86 against an industry PE of 36.42, valuation should be checked against that growth before investing.
What is the market cap of Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin?
Ans. As of 22 October 2026, Sun Pharma has a market cap of Rs 4,22,427 crore, Divi’s Labs has a market cap of Rs 2,39,982 crore, Torrent Pharma has a market cap of Rs 1,75,196 crore and Lupin has a market cap of Rs 89,592 crore. Sun Pharma is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Nifty Pharma stocks.
What are the risks of investing in Nifty Pharma stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Divi’s Labs trades at a PE of 82.05 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Divi’s Labs trading at a PE of 82.05?
Ans. Divi’s Labs’ PE of 82.05 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 15.32% and latest-quarter profit growth of 65.50%, which also means the stock is more sensitive if growth slows. Investors in Nifty Pharma stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Sun Pharma, Divi’s Labs, Torrent Pharma and Lupin?
Ans. As of the latest reported quarter, FII and DII together hold 36.63% of Sun Pharma (14.36% and 22.27%), 39.55% of Divi’s Labs (20.38% and 19.17%), 30.84% of Torrent Pharma (17.97% and 12.87%) and 47.07% of Lupin (22.42% and 24.65%). Rising institutional holding is a useful signal in Nifty Pharma stocks, though it should be read with earnings trends rather than on its own.
